School of Pharmacy, Second Military Medical University, Shanghai, China.
School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
Biomed Pharmacother. 2020 Nov;131:110572. doi: 10.1016/j.biopha.2020.110572. Epub 2020 Aug 21.
Long non-coding RNA (lncRNA) was once considered to be the "noise" of genome transcription without biological function. However, increasing evidence shows that lncRNA is dynamically expressed in developmental stage or disease status, playing a regulatory role in the process of gene expression and translation. In recent years, lncRNA is considered to be a core node of functional regulatory networks that controls cardiac and also involves in multiple process of heart failure such as myocardial hypertrophy, fibrosis, angiogenesis, etc., which would be a therapeutic target for diseases. In fact, it is the development of technology that has improved our understanding of lncRNAs and broadened our perspective on heart failure. From transcriptional "noise" to star molecule, progress of lncRNAs can't be achieved without the combination of multidisciplinary technologies, especially the emergence of high-throughput approach. Thus, here, we review the strategies and technologies available for the exploration lncRNAs and try to yield insights into the prospect of lncRNAs in clinical diagnosis and treatment in heart failure.
长链非编码 RNA（lncRNA）曾一度被认为是基因组转录的“噪声”，没有生物学功能。然而，越来越多的证据表明，lncRNA 在发育阶段或疾病状态下是动态表达的，在基因表达和翻译过程中发挥着调节作用。近年来，lncRNA 被认为是控制心脏功能的功能调节网络的核心节点，也参与心力衰竭的多个过程，如心肌肥大、纤维化、血管生成等，这将成为疾病的治疗靶点。事实上，正是技术的发展提高了我们对 lncRNA 的认识，并拓宽了我们对心力衰竭的看法。从转录“噪声”到明星分子，如果没有多学科技术的结合，尤其是高通量方法的出现，lncRNA 的进展是不可能实现的。因此，在这里，我们回顾了探索 lncRNA 的策略和技术，并试图深入了解 lncRNA 在心力衰竭的临床诊断和治疗中的前景。
